Inotek Pharmaceuticals to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that David P. Southwell, President and Chief Executive Officer of Inotek, will present a company overview at the following conferences:

• Cantor Fitzgerald’s 2nd Annual Healthcare Conference on, July 12th, 2016 at 1:30 p.m. EDT in New York City.
• Canaccord Genuity 36th Annual Growth Conference on, August 10th, 2016 at 10:00 a.m. EDT in Boston, MA.

A live audio webcast of the Cantor Fitzgerald presentation will be available on the Investors section of the company’s website, www.inotekpharma.com. A replay of the presentation will be archived on the Inotek website following the conference.

About Inotek Pharmaceuticals CorporationInotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit www.inotekpharma.com.

Forward-Looking StatementsThis press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These forward-looking statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160708005103/en/

Inotek Pharmaceuticals
Claudine Prowse, Ph.D., 781-552-4305
Vice President, Strategy and Investor Relations Officer
[email protected]

Source: Inotek Pharmaceuticals

You May Also Be Interested In

• Rare Houston Meteorite Event Brings Dozens Of New Photos To The Public
• Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
• Can HYPE Hit $100? Hyperliquid Momentum Builds as MemeToro Targets the Next AI Crypto Wave